Immuneering Corporation
IMRX
$3.96
-$0.08-1.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.98M | 17.30M | 16.50M | 16.01M | 15.97M |
| Depreciation & Amortization | 29.20K | 29.20K | 29.20K | 29.20K | 29.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.23M | 59.38M | 64.18M | 64.07M | 64.23M |
| Operating Income | -59.23M | -59.38M | -64.18M | -64.07M | -64.23M |
| Income Before Tax | -54.44M | -56.02M | -62.50M | -62.13M | -61.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.44 | -56.02 | -62.50 | -62.13 | -61.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.44M | -56.02M | -62.50M | -62.13M | -61.77M |
| EBIT | -59.23M | -59.38M | -64.18M | -64.07M | -64.23M |
| EBITDA | -58.88M | -59.02M | -63.82M | -63.70M | -63.85M |
| EPS Basic | -1.17 | -1.38 | -1.78 | -1.90 | -1.97 |
| Normalized Basic EPS | -0.73 | -0.86 | -1.12 | -1.19 | -1.23 |
| EPS Diluted | -1.17 | -1.38 | -1.78 | -1.90 | -1.97 |
| Normalized Diluted EPS | -0.73 | -0.86 | -1.12 | -1.19 | -1.23 |
| Average Basic Shares Outstanding | 204.90M | 175.78M | 142.24M | 132.41M | 126.08M |
| Average Diluted Shares Outstanding | 204.90M | 175.78M | 142.24M | 132.41M | 126.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |